Antibody Drug Conjugates(ADCs) are approved for use in cancers.
Cardiovascular adverse reaction is a fatal adverse reactions associated with ADCs.
The incidence of adverse cardiac events about ADCs have not been fully studied.
We aimed to assess differences in cardiotoxicity among cancer patients treated with different ADCs.
